Subscribe via RSS- NEWS ARCHIVES
-
2008
2007
2006
2005
2004
Pharma & Bio Ingredients
"Techniques for scalable and cost-effective hESC manufacturing are key to our product-based business model for hESC therapies for degenerative diseases," said Thomas B. Okarma Ph.D., M.D., Geron's President and Chief Executive Officer. "Geron scientists pioneered feeder-free growth of the cells. We continue to build on that work by developing new and improved approaches to hESC production. The availability of appropriate synthetic growth surfaces will benefit both Geron and the field of hESC research more broadly. Corning is a world-leader in cell culture surfaces, and we are excited to partner with the company in these efforts."
"Corning is equally excited to partner with a world-leader in stem cell biology such as Geron," said Jeff Mooney, Ph.D., Director of Commercial Technology for Corning Life Sciences. "We are committed to bringing our core expertise in materials, surfaces, biology, and process engineering to enhance current methods of cell growth and bring innovative products to the life sciences market."
A major advantage of hESCs over other types of stem cells is their ability to maintain pluripotency and proliferative capacity indefinitely in culture. This allows for the scalable expansion of the undifferentiated cells prior to differentiation into therapeutic cell populations. Conventionally, hESCs have been grown on a supporting layer of mouse or human feeder cells that supplied growth factors needed to maintain the pluripotency of the cells. Geron scientists have developed techniques for growing hESCs without feeder cells. This can increase the scalability and reproducibility of hESC manufacturing while eliminating the risk of contamination by infectious agents from the feeder cells. Synthetic growth surfaces on which hESCs will grow could replace the currently used biological surface coatings and lead to greater uniformity and cost savings.
